Login / Signup

Multivalent Aptamer-Based Lysosome-Targeting Chimeras (LYTACs) Platform for Mono- or Dual-Targeted Proteins Degradation on Cell Surface.

Qiao DuanHao-Ran JiaWeichang ChenChunhong QinKejing ZhangFei JiaTing FuYong WeiMengyang FanQin WuWeihong Tan
Published in: Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2024)
Selective protein degradation platforms have opened novel avenues in therapeutic development and biological inquiry. Antibody-based lysosome-targeting chimeras (LYTACs) have emerged as a promising technology that extends the scope of targeted protein degradation to extracellular targets. Aptamers offer an advantageous alternative owing to their potential for modification and manipulation toward a multivalent state. In this study, a chemically engineered platform of multivalent aptamer-based LYTACs (AptLYTACs) is established for the targeted degradation of either single or dual protein targets. Leveraging the biotin-streptavidin system as a molecular scaffold, this investigation reveals that trivalently mono-targeted AptLYTACs demonstrate optimum efficiency in degrading membrane proteins. The development of this multivalent AptLYTACs platform provides a principle of concept for mono-/dual-targets degradation, expanding the possibilities of targeted protein degradation.
Keyphrases
  • cancer therapy
  • protein protein
  • amino acid
  • high throughput
  • cell surface
  • gold nanoparticles
  • drug delivery
  • small molecule
  • sensitive detection
  • fluorescent probe
  • living cells
  • single molecule
  • quantum dots
  • single cell